

SCHOTT Pharma | 2025


Facts & Figures



Global Footprint

17 state-of-the-art production facilities

15 countries, including all major pharma hubs



100% focus
on our core expertise

Pharma drug containment and
delivery solutions



€957 million revenues

€258 million EBITDA

(+12% at constant
currencies)

Margin: 26.9 %



>1,000

patents and designs
developed

>120

employees
active in R&D collaborating
with an exclusive network
of partners

On average, more than 25,000 injections per minute
are provided to patients worldwide through a SCHOTT Pharma product.

>12

billion products
delivered every year



Glass
syringes



Polymer
syringes



Cartridges



Vials



Ampoules



Broad
ready-to-use
portfolio




Market & Customers


The top 30 global pharma companies use SCHOTT Pharma's solutions.

>1,800


customers worldwide



Big pharma innovators



Leading CDMOs



Biotechs & start-ups

<h2>Growth opportunities from structural trends</h2>	
<div><h3>mRNA therapies</h3><p>New drug categories require deep-cold storage (-100°C)</p><div><div>✓</div><p>SCHOTT Pharma currently offers the only prefillable syringes for these applications¹</p></div></div>	<div><h3>GLP-1 drugs</h3><p>Increasing demand to treat type-2 diabetes, obesity</p><div><div>✓</div><p>SCHOTT Pharma has long-term contracts with the leading GLP-1 players</p></div></div>
<div><h3>Homecare solutions</h3><p>Enabling patients to inject drugs at home, reducing healthcare cost</p><div><div>✓</div><p>SCHOTT Pharma contributes to fully integrated systems from device manufacturers</p></div></div>	<div><h3>Manufacturing transformation</h3><p>Smaller patient populations require more flexible filling lines</p><div><div>✓</div><p>SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility</p></div></div>
<div><h3>Subcutaneous injections</h3><p>Subcutaneous large-volume injections of biologics are more patient-friendly</p><div><div>✓</div><p>SCHOTT Pharma's cartridges and syringes feature precise geometry to ensure accurate dosing and reducing injection forces</p></div></div>	<div><h3>Antibody-drug conjugates (ADCs)</h3><p>Innovative ADC therapies need to be lyophilized to ensure drug efficacy</p><div><div>✓</div><p>SCHOTT Pharma offers specialty vials that fully eliminate fogging thanks to a hydrophobic inner coating</p></div></div>

¹No competitor disclosed a product with mentioned specifications so far



SCHOTT Pharma

ESG Responsibility



↓

60%
reduced CO₂
emissions since 2019¹

→

100 %
Already using green
electricity worldwide


~4.700
employees from over

60
nationalities

>40%
female employees

~24 %
of leadership positions
held by women



Ownership



Executive Board



Andreas Risse
CEO

Over 35 years of experience

Heading SCHOTT's pharma business since 2010

Previously headed SCHOTT's Tubing business unit

Master's Degree in Industrial Engineering



Reinhard Mayer
CFO

Over 30 years of experience

CFO of SCHOTT Pharma since 2025

Previous CFO roles with Nilfisk Holding, Hansgrohe, and Getinge Group

Master's Degree in Industrial Engineering

¹ Scope 1 & 2; Defined as corporate CO2 footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)



SCHOTT Pharma's Governance

KGaA (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three corporate bodies:



General partner
(Komplementär)



Supervisory board
(Aufsichtsrat)



General shareholders' meeting
(Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

Supervisory Board

Shareholder representatives



Peter Goldschmidt
CEO
Stada AG



Dr. Wolfram Carius
Executive Vice President
Bayer AG



Eva Kienle
CFO
KWS Saat SE & Co. KGaA



Ann-Kristin Erkens
CFO
SIG Group AG

Employee representatives



Mario Just
SCHOTT Pharma



Christine Wening
SCHOTT Pharma

Press contact



Lea Kaiser



lea.kaiser@schott.com



+49 (0) 151/68 91 71 95

